clinical trial · NCT05680818
Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1
Calcilytix Therapeutics, Inc., a BridgeBio company·phase3·active not recruiting·n = 67
Autosomal Dominant Hypocalcemia (ADH)EncaleretStandard of Care
brief summary
The primary purpose of the study is to understand the effectiveness, safety, and tolerability of encaleret when compared to standard of care (SoC) treatment in participants with Autosomal Dominant Hypocalcemia Type 1 (ADH1).
started
Jan 6, 2023
primary completion
Aug 22, 2025
completion
Aug 1, 2029
last updated
Oct 31, 2025
official title
CALIBRATE: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol